Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I’ve been here since 2010, hoping for a cure for HIV. If this happens, I’m going to Vegas regardless of price action.
Signed.
Good luck Saltz! Maybe put DolphinTom on speed dial to help with your exit decision. I’m betting there’ll be a college auditorium with your name on it in the future.
Thanks for always being the light in the dark, the calm in the crazy, and the boot in Dr NP’s as- when needed. The only thing sweeter would be if the SEC sent that rebuttal to AF, certified.
If you’re considering expanding your business into other states, you will need to know about “foreign qualification.”
The terminology can be confusing. Foreign qualification can sound like an international concept. But in the eyes of the state governing authorities for all entity types—including U.S. corporations, limited liability companies (LLCs), limited partnerships (LPs), and limited liability partnerships (LLPs)—“foreign” in this case doesn’t mean operating outside of the United States. Foreign refers to a state or jurisdiction other than the entity’s state of formation.
https://www.bizfilings.com/toolkit/research-topics/launching-your-business/planning/doing-business-outofstate-foreign-qualification
Happy Birthday D0lphinT0m! Thanks for all your wisdom over the years! Enjoy your day!
Dr Daniel Linder M.D., Ph.D. At the Cleveland Clinic - human colon carcinoma - article from Aug 2019. I’m in the middle of something at work or I’d post the link.
Didn’t we run a trial for another indication at the Cleveland Clinic? I’ll try and search for the lead doctor there that was involved.
I’m looking forward to hearing from our CRO. We are not well known. many of us Longs believe leronlimab can improve your quality of life or in mTNBC, save it, same with COVID19. Dr NP’s updates have reached another woman with mTNBC in Ireland and she’s traveling to San Fran in 2 weeks. Hopefully she makes it. Dr Yo can’t get the ICU he trained at to consider Leronlimab for his mentor. Makes me want to scream. I think these presentations with our medical team are necessary, they may reach someone in need.
No credibility? His patient is alive. Here’s a couple quotes from the CBS News LA report. What is your goal with all the negativity regarding this treatment? Are your writing here to prevent people from seeking this treatment? What’s your goal?
“”At this point, doctors can’t know for sure whether “leronlimab” is solely responsible for Mottet’s recovery. However, Yang said he believes there is strong evidence to support this theory.
“In 24 hours, she started requiring less oxygen on the ventilators, and 48 hours after that, she was able to come off the ventilator all together,” Yang said. ‘Then a couple of days after that, she didn’t require any oxygen at all.””
Heart wrenching.
I agree, but I’d like to see some revenue this year.
Happy Birthday Misiu!
I agree with you and I guess I don’t understand the process - why wouldn’t the data be collected in a format that the FDA requires to begin with? Can anyone who’s been a part of these studies offer any insight to me? Why would the data always be tabulated in this format? When companies come into our “data room” what are they looking at?
Bravo! Well done!
External help such as Amarex? http://amarexcro.com/
I think this “article” served its purpose in Culpers desire to manipulate the stock downward. Their research is incomplete and they present it as complete. Dr NP spent approximately four years as our Operations Officer. They didn’t mention that.
They didn’t interview Amarex or Dr Dhody, even though he’s been at most of the medical presentations , CROI 2019, as an example. They didn’t mention the Italian research group that tested Leronlimab in Italy and is presenting at CROI 2020. And furthermore they didn’t mention one word about Dr Sacha and his presentation to CROI 2020.
They didn’t interview the original inventor of the molecule, and he also attends the medical presentations.
I could continue, but I have a meeting at 10:00. Their research is incomplete and as such is pure stock manipulation and I’m certain will be reported to the SEC.
Proud bag holder here.
2010 Allen D Allen was still around.
well, Grip made his peace last week and probably went away for the holidays. no one has missed anything yet, I'm still below some of my basis, so its not too late to jump back in. live and let live and be kind
Happy for you Bobbyinvest!
Did you buy dolphinTom’s book on tech analysis?
You need to write to the board as they have dictated the small cash raise strategy. And, they are the ones who keep Dr NP in his position and just gave him a raise. Lawman provided all of their information and I believe that info is stuck at the top of this. Posting your demands here does nothing.
We're close to 2myn shares trading today, but what percentage of the total is that? less than 1 percent. Its a clinical stage biotech and it sucks when it sucks, but the science and potential upside are life changers.
Can't help anyone who buys a biotech on margin, or puts the stock on margin without 100k room for market fluctuation.
Good luck to all. Hang in there.
I heard first patient in protocol was screened yesterday
“Doing now what patients need next”. I like their corporate culture.
The mTNBC clinical trial appears on Northwestern University’s clinical trials website. I’ve been traveling and I don’t know if this is old news - I had been checking frequently and first time I checked in a bit and it’s there!!
We paid quite a high price for Dr RP and they should have put more effort into merging the divergent personalities. Rather than spending $8,300 on office space in south Florida, they should have hired a couple administrators - or better yet used some of that free PhD labor you refer to on DR RP’s to do list at CytoDyn. The TNBC was Dr RP’s baby and he blew it. Project management 101 - make certain your investigator in under contract. Sheesh didn’t he generate a project list and timeline and identify personnel responsibilities. Did Dr Massimino and he not speak? Wouldn’t he be asking where’s my contract? I would.
The conference call before the merger he said he’d been in discussions about selling his prostate cancer test. He certainly didn’t mention that we have to hire another doctor who owns the data to crunch numbers.
I have personal reasons for backing the prostate and breast cancer initiatives and am pissed at what has transpired.
Dr RP has to fight for his reputation because no one wants to hire an expert witness with an asterisk by their name. Google him - that expert witness gig pays well - and that’s at the top of the Google list.
I’m less than enthusiastic about Dr Berger returning.
I am enthusiastic about NASH and PReP and the doctors they’ve collaborated with on these initiatives.
Dr NP needs to submit the BLA. I’m growing weary of his dangling carrot. People need Leronlimab-
Scam? Well we have a third party conducting our clinical trials in HIV, so that word is a stretch. We have others conducting trials of their own with Leronlimab,Dr Sacha, which are funded by AIDS research organizations so don’t get too ahead of the facts before all is in the open. Am I dismayed by what I read, yes, but what has been achieved to date on a shoestring budget is real.
Fidelity
Appreciate all of your posts on GTEC.
While the one TNBC patient hopefully being treated with compassionate care is meaningless to the numbers in the test, if she has positive results the other centers will have a positive result to point to. I wouldn’t categorize that as meaningless
Dr Sacha mentioned flying to NYC to meet with reps from amFAR , not a pharmaceutical firm, they are interested in funding his research. He has a grant from NIH for his research in Prep with Leronlimab
I’d recommend everyone listen to the call replay, especially Dr Sacha and the preclinical work he is doing with primates funded by NIH grant and he’s personally going to NYC on Friday to secure funding from amFAR for additional tests using Leronlimab.
Well done! Thank you
Well since this grenade was thrown the price has held surprisingly well.
Are you kidding? Why would a company in the process of submitting a BLA risk everything at this stage. Makes no sense. There will always be affluent people in the 1 pct adversely affected by cancer or HIV willing to open their wallets in the memory of a loved one.
Here’s what I see - the TNBC site that is recruiting is working with Anarex Clinical Research, the same firm that Dr NP contracted to lead our HIV tests. The sites organized by Dr RP and his former research partners at Thomas Jefferson Hospital have yet to start. I don’t know that Dr NP is the problem here. IR said the dates for the trial start and first injections came from Dr RP. So we just don’t know what transpired, we can only speculate.
Well you don’t speak for me. I have a strong position and believe in the science. It’s a biotech so you have to expect dilution. We have a ways to go but we’re much closer to revenue. Our management is very passionate about how this monoclonal antibody will improve the lives of those with HIV and potentially some metastatic cancer. In fact our President and CEO’s father is using it for his prostate cancer. I’m very bullish on the long term price of this stock.
Good grief they posted a SEC required document. Everything else you are typing is conjecture.
Chump - hope you and yours are out of danger from this storm.
What’s your average price?